BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 23074282)

  • 41. Consensus JH gene probes with conjugated 3'-minor groove binder for monitoring minimal residual disease in acute lymphoblastic leukemia.
    Uchiyama M; Maesawa C; Yashima-Abo A; Tarusawa M; Endo M; Sugawara W; Chida S; Onodera S; Tsukushi Y; Ishida Y; Tsuchiya S; Masuda T
    J Mol Diagn; 2005 Feb; 7(1):121-6. PubMed ID: 15681483
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia.
    Eckert C; Landt O; Taube T; Seeger K; Beyermann B; Proba J; Henze G
    Leukemia; 2000 Feb; 14(2):316-23. PubMed ID: 10673751
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia.
    Verhagen OJ; Willemse MJ; Breunis WB; Wijkhuijs AJ; Jacobs DC; Joosten SA; van Wering ER; van Dongen JJ; van der Schoot CE
    Leukemia; 2000 Aug; 14(8):1426-35. PubMed ID: 10942239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
    Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators.
    Van der Straeten J; De Brouwer W; Kabongo E; Dresse MF; Fostier K; Schots R; Van Riet I; Bakkus M
    J Mol Diagn; 2021 May; 23(5):599-611. PubMed ID: 33549860
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable region specific oligonucleotide probes.
    Jonsson OG; Kitchens RL; Scott FC; Smith RG
    Blood; 1990 Nov; 76(10):2072-9. PubMed ID: 2122920
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Minimal residual disease detection in Tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements.
    Besbes S; Hamadou WS; Boulland ML; Youssef YB; Achour B; Regaieg H; Khelif A; Fest T; Soua Z
    Braz J Med Biol Res; 2017 Jan; 50(1):e5426. PubMed ID: 28099581
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection and management of minimal residual disease in acute lymphoblastic leukemia.
    Schrappe M
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):244-9. PubMed ID: 25696862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in childhood acute lymphoblastic leukemia using a low-cost PCR strategy.
    Assumpção JG; Ganazza MA; de Araújo M; Silva AS; Scrideli CA; Brandalise SR; Yunes JA
    Pediatr Blood Cancer; 2010 Dec; 55(7):1278-86. PubMed ID: 20730889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukaemia by single-strand conformation polymorphism studies and highly resolutive PCR derived methods: implication for a general strategy of minimal residual disease detection.
    Baruchel A; Cayuela JM; MacIntyre E; Berger R; Sigaux F
    Br J Haematol; 1995 May; 90(1):85-93. PubMed ID: 7786801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-time quantitative PCR: standardized detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Polymerase chain reaction.
    Pine SR; Moy FH; Wiemels JL; Gill RK; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C; Jayabose S
    J Pediatr Hematol Oncol; 2003 Feb; 25(2):103-8. PubMed ID: 12571459
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.
    Nakao M; Janssen JW; Flohr T; Bartram CR
    Cancer Res; 2000 Jun; 60(12):3281-9. PubMed ID: 10866322
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse.
    Lal A; Kwan E; al Mahr M; Zhou L; Ferrara D; Tobias V; O'Gorman Hughes D; Haber M; Norris MD; Marshall GM
    Mol Pathol; 1998 Oct; 51(5):277-81. PubMed ID: 10193523
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis?
    Chen X; Wood BL
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):237-248. PubMed ID: 29050697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: a PCR-based assay employing overlapping DJH primers.
    Norris MD; Kwan E; Haber M; Marshall GM
    Leukemia; 1995 Oct; 9(10):1779-82. PubMed ID: 7564525
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction.
    Nizet Y; Van Daele S; Lewalle P; Vaerman JL; Philippe M; Vermylen C; Cornu G; Ferrant A; Michaux JL; Martiat P
    Blood; 1993 Sep; 82(5):1618-25. PubMed ID: 8364210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience.
    Kolenova A; Hikkel I; Ilencikova D; Hikkelova M; Sejnova D; Kaiserova E; Cizmar A; Puskacova J; Bubanska E; Oravkinova I; Gencik M
    Neoplasma; 2010; 57(6):552-61. PubMed ID: 20845994
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic changes: relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukaemia.
    Cole-Sinclair MF; Foroni L; Hoffbrand AV
    Baillieres Clin Haematol; 1994 Jun; 7(2):183-233. PubMed ID: 7803899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Minimal residual disease in childhood acute leukemias].
    Pawińska K; Balwierz W; Baran J
    Przegl Lek; 2006; 63(1):41-3. PubMed ID: 16892899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.